AstraZeneca R&D Montréal, Ville St-Laurent, Montréal, Québec H4S 1Z9, Canada.
J Neurosci. 2012 Aug 22;32(34):11890-6. doi: 10.1523/JNEUROSCI.0698-12.2012.
Evidence suggesting the involvement of P2X2 and P2X3 in chronic pain has been obtained mostly from rodent models. Here we show that rodents may be poor predictors of P2X3 pharmacology in human. We demonstrate that monkey and human dorsal root ganglion (DRG) neurons do not express appreciable levels of P2X2 subunit, contrary to rat sensory neurons. Additionally, we report functional P2X3 activity in monkey DRG neurons and confirm the absence of functional P2X2/3 receptors. Interestingly, native P2X3 receptors in rat and monkey DRGs show similar agonist potency, but different antagonist potencies for TNP-ATP [2-O-(2,4,6-trinitrophenyl)-ATP] and RO51. This unexpected difference in antagonist potency was confirmed by comparing rat and human P2X3 receptors in HEK293 cells. Mutagenesis studies reveal that two extracellular residues, A197 and T202, are synergistically responsible for the potency drop in primate P2X3 receptors. These results uncover species-specific P2X3 pharmacology and identify key mechanisms impacting the translatability of potential analgesics targeting P2X3 receptors.
有证据表明,P2X2 和 P2X3 参与了慢性疼痛,这些证据主要来自于啮齿动物模型。在这里,我们表明,啮齿动物可能无法准确预测人类 P2X3 药理学。我们证明,猴子和人类背根神经节 (DRG) 神经元不像大鼠感觉神经元那样表达大量的 P2X2 亚基。此外,我们报告了猴子 DRG 神经元中功能性 P2X3 活性,并证实不存在功能性 P2X2/3 受体。有趣的是,大鼠和猴子 DRG 中的天然 P2X3 受体表现出相似的激动剂效力,但对 TNP-ATP [2-O-(2,4,6-三硝基苯膦基)-ATP] 和 RO51 的拮抗剂效力不同。通过比较大鼠和人 P2X3 受体在 HEK293 细胞中的表达,证实了这种出乎意料的拮抗剂效力差异。突变研究表明,两个细胞外残基 A197 和 T202 协同作用导致灵长类 P2X3 受体的效力下降。这些结果揭示了种属特异性的 P2X3 药理学,并确定了影响潜在针对 P2X3 受体的镇痛药可转化性的关键机制。